目的探讨改良生物补片重建盆底腹膜(modified biological patch for reconstruction of pelvic floor peritoneum,MBR)用于腹腔镜Miles手术的安全性和临床效果。方法回顾性分析2015年1月至2018年12月在山东省立医院胃肠外科接受腹腔镜Mi...目的探讨改良生物补片重建盆底腹膜(modified biological patch for reconstruction of pelvic floor peritoneum,MBR)用于腹腔镜Miles手术的安全性和临床效果。方法回顾性分析2015年1月至2018年12月在山东省立医院胃肠外科接受腹腔镜Miles手术的343例低位直肠癌病人的临床资料。按纳入和排除标准,303例病人纳入研究,根据是否行MBR,将病人分为MBR组(47例)和未重建(Non-MBR)组(256例)。研究中使用的生物补片取材于牛心包组织,是一种交联脱细胞基质材料。比较两组的术中和术后结果,并介绍MBR方法和安全性。结果与Non-MBR组相比,MBR组术后粘连性小肠梗阻(adhesive small bowel obstruction,ASBO)的发生率降低(0比10.9%,P<0.05),术后因ASBO的再次住院率降低(0比9.8%,P<0.05)。Non-MBR组术后因ASBO平均再次住院次数为1.8次。MBR组重建盆底腹膜时间为(3.3±0.8)min,该组病人随访1年未出现生物补片排异、感染、侵蚀、磨损等不良反应。两组手术时间、术中出血量、术后首次排气时间、术后住院时间、会阴切口液化、感染、会阴疝的发生率、因会阴切口感染、会阴疝的再次住院率差异无统计学意义。结论MBR在腹腔镜Miles手术中安全易行、耗时较少,可降低术后ASBO的发生率及因ASBO再住院率。此外,交联脱细胞基质材料生物补片具有良好的组织相容性,具有临床实用价值。展开更多
腹腔手术后,部分患者术后易发生肠粘连或肠梗阻,如多次手术可发生短肠综合征或肠瘘.为此,我们应用M-A管排列术配合完全肠道外营养(TPN)治疗小儿粘连性肠梗阻共3例.取得了满意疗效.典型病例: 男,12岁.因肠梗阻术后发生粘连性肠梗阻及肠瘘...腹腔手术后,部分患者术后易发生肠粘连或肠梗阻,如多次手术可发生短肠综合征或肠瘘.为此,我们应用M-A管排列术配合完全肠道外营养(TPN)治疗小儿粘连性肠梗阻共3例.取得了满意疗效.典型病例: 男,12岁.因肠梗阻术后发生粘连性肠梗阻及肠瘘,历时14个月不愈.入院时检查:体重27.公斤,H b 3.7克,A/G=2.6/1.3,腹胀,腹部皮肤糜烂并见大便外溢.入院后行TPN治疗,禁食不禁水,输血,应用抗生素等.10天后手术.展开更多
Objective: To evaluate the relationship between the pelvic and para-aortic lymphadenectomy and the prognosis of epithelial ovarian cancer. Methods: 287 patients suffering from primary epithelial ovarian cancer from 19...Objective: To evaluate the relationship between the pelvic and para-aortic lymphadenectomy and the prognosis of epithelial ovarian cancer. Methods: 287 patients suffering from primary epithelial ovarian cancer from 1995 to 2005 were analyzed retrospectively. Results: The 3-, 5-, 10-year survival with systematic lymphadenectomy (SL) were slightly higher than those without SL, but there were no statistically significance (P > 0.05). The 3-, 5-, 10-year survival of clinical stages without SL were lower than those with SL, but there were no significant difference either (P > 0.05). The 3-,5-, and 10-year survival rates with SL were higher than those without SL with no statistically differences (P > 0.05) among the subgroups such as absent, ≤ 2 cm and > 2 cm residual tumor. The survival rates of the groups without residual tumor and the group with ≤ 2 cm residual tumor were significantly higher than that of > 2 cm (P < 0.005). On multivariate analysis, patient staging (P = 0.01) and size of residual disease after primary cytoreductive surgery (P < 0.001 and = 0.002, respectively) retained prognostic significance. SL was not proved to be an independent prognostic factor (P = 0.69). Conclusion: Systematic pelvic and para-aortic lymphadenectomy can not improve and prolong the survival time significantly.展开更多
文摘目的探讨改良生物补片重建盆底腹膜(modified biological patch for reconstruction of pelvic floor peritoneum,MBR)用于腹腔镜Miles手术的安全性和临床效果。方法回顾性分析2015年1月至2018年12月在山东省立医院胃肠外科接受腹腔镜Miles手术的343例低位直肠癌病人的临床资料。按纳入和排除标准,303例病人纳入研究,根据是否行MBR,将病人分为MBR组(47例)和未重建(Non-MBR)组(256例)。研究中使用的生物补片取材于牛心包组织,是一种交联脱细胞基质材料。比较两组的术中和术后结果,并介绍MBR方法和安全性。结果与Non-MBR组相比,MBR组术后粘连性小肠梗阻(adhesive small bowel obstruction,ASBO)的发生率降低(0比10.9%,P<0.05),术后因ASBO的再次住院率降低(0比9.8%,P<0.05)。Non-MBR组术后因ASBO平均再次住院次数为1.8次。MBR组重建盆底腹膜时间为(3.3±0.8)min,该组病人随访1年未出现生物补片排异、感染、侵蚀、磨损等不良反应。两组手术时间、术中出血量、术后首次排气时间、术后住院时间、会阴切口液化、感染、会阴疝的发生率、因会阴切口感染、会阴疝的再次住院率差异无统计学意义。结论MBR在腹腔镜Miles手术中安全易行、耗时较少,可降低术后ASBO的发生率及因ASBO再住院率。此外,交联脱细胞基质材料生物补片具有良好的组织相容性,具有临床实用价值。
文摘腹腔手术后,部分患者术后易发生肠粘连或肠梗阻,如多次手术可发生短肠综合征或肠瘘.为此,我们应用M-A管排列术配合完全肠道外营养(TPN)治疗小儿粘连性肠梗阻共3例.取得了满意疗效.典型病例: 男,12岁.因肠梗阻术后发生粘连性肠梗阻及肠瘘,历时14个月不愈.入院时检查:体重27.公斤,H b 3.7克,A/G=2.6/1.3,腹胀,腹部皮肤糜烂并见大便外溢.入院后行TPN治疗,禁食不禁水,输血,应用抗生素等.10天后手术.
文摘Objective: To evaluate the relationship between the pelvic and para-aortic lymphadenectomy and the prognosis of epithelial ovarian cancer. Methods: 287 patients suffering from primary epithelial ovarian cancer from 1995 to 2005 were analyzed retrospectively. Results: The 3-, 5-, 10-year survival with systematic lymphadenectomy (SL) were slightly higher than those without SL, but there were no statistically significance (P > 0.05). The 3-, 5-, 10-year survival of clinical stages without SL were lower than those with SL, but there were no significant difference either (P > 0.05). The 3-,5-, and 10-year survival rates with SL were higher than those without SL with no statistically differences (P > 0.05) among the subgroups such as absent, ≤ 2 cm and > 2 cm residual tumor. The survival rates of the groups without residual tumor and the group with ≤ 2 cm residual tumor were significantly higher than that of > 2 cm (P < 0.005). On multivariate analysis, patient staging (P = 0.01) and size of residual disease after primary cytoreductive surgery (P < 0.001 and = 0.002, respectively) retained prognostic significance. SL was not proved to be an independent prognostic factor (P = 0.69). Conclusion: Systematic pelvic and para-aortic lymphadenectomy can not improve and prolong the survival time significantly.
